Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 09 2022
Historique:
received: 07 03 2022
revised: 03 06 2022
accepted: 12 07 2022
pubmed: 26 7 2022
medline: 9 9 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Immunoglobulin light chain (AL) amyloidosis is a life-threatening systemic disease due to plasma cell dyscrasias, which is characterized by amyloid deposition in various tissues. Neurological manifestations, in particular peripheral nervous system involvement, play a major role for quality of life and treatment decisions as frequently potentially neurotoxic drugs are used. We retrospectively investigated the prevalence of neurological manifestations, its risk factors and prognostic value in 155 consecutive patients with AL amyloidosis in a single German tertiary center between 2010 and 2021. Multiple logistic regression was performed to identify predictors of amyloid neuropathy and the impact of peripheral neuropathy on patient survival was assessed by Cox proportional hazard regression analysis. Nearly half of patients showed at least one of four neurological manifestations of AL amyloidosis which were frequent in our study: peripheral neuropathy (36.8%), carpal tunnel syndrome (12.9%), lumbar spinal stenosis (7.1%), and amyloid myopathy (3.9%). Male sex (OR 2.943, CI 1.152-8.139, p = 0.029) and cardiac involvement (OR 6.186, CI 1.449-43.38, p = 0.028) were independent predictors of peripheral neuropathy which was closely related to autonomic dysfunction in patients with AL amyloidosis. Peripheral neuropathy had no impact on survival (HR 0.952, CI 0.517-1.754, p = 0.876). Neurological involvement is common in systemic AL amyloidosis. Treatment decisions should take into account peripheral neuropathy, in particular in male patients with amyloid cardiomyopathy, but also amyloid myopathy that seems to be not as rare as previously suggested.

Identifiants

pubmed: 35872471
pii: S0022-510X(22)00203-9
doi: 10.1016/j.jns.2022.120341
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120341

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Andreas Thimm (A)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Essen, Germany. Electronic address: andreas.thimm@uk-essen.de.

Alexander Carpinteiro (A)

Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany; Institute of Molecular Biology, University of Duisburg-Essen, Essen, Germany.

Sara Oubari (S)

Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.

Maria Papathanasiou (M)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.

Peter Luedike (P)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.

Lukas Kessler (L)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

Christoph Rischpler (C)

Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.

Tobias Blau (T)

Institute of Neuropathology, University Hospital Essen, Essen, Germany.

Hans Christian Reinhardt (HC)

Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.

Tienush Rassaf (T)

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.

Hartmut Schmidt (H)

Department of Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany.

Christoph Kleinschnitz (C)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Essen, Germany.

Tim Hagenacker (T)

Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH